% | $
Quotes you view appear here for quick access.

Zalicus AŞ Message Board

jmyzal22 15 posts  |  Last Activity: 17 hours ago Member since: Mar 19, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • by jmyzal22 17 hours ago Flag

    Very excited about dur-928. another condition to be indicated that they're not ready to discuss. Bio markers if move will send us in the spot light with just a single dose.
    Posimir it is my feeling they want to partner this soon. So the partner gets to have a great marketing advantage. Remoxy pain wants to partner. Data against Purdue next week. My assumption is with a growing field in 505-b2 drugs this will call for OxyContin to come off the market.


    Sentiment: Strong Buy

  • Reply to


    by svksudupa Apr 25, 2016 5:29 PM jmyzal22 Apr 25, 2016 6:29 PM Flag

    Not sure, I believe they announced something similar to this last November.

  • by jmyzal22 Apr 20, 2016 8:51 PM Flag

    Would it be unheard of for Pfizer to partner with Pain's Remoxy again?

  • by jmyzal22 Apr 11, 2016 1:22 AM Flag

    Posimir the market reacted to the news. Seems it determined it was a minor setback. NDA is a slam dunk on Remoxy. DUR-928 speculation could send this up 5-10 fold down the road. Should get positive news on single dose in Nash patients. Wild card ZGNX partnering Relday, I think we'll get Orient Pharma data on ADHD phase 3 trial in September. long strong

    Side note: ELTP=trash

    Sentiment: Strong Buy

  • Reply to

    Posimir is positively killing this stock

    by martinmcflyyy Apr 10, 2016 6:18 PM jmyzal22 Apr 11, 2016 1:02 AM Flag

    ELTP= penny stock pump dump.
    Insiders selling.
    Drug won't be approved
    600,000,000 OS

  • Reply to

    More time and cost for POSIMIR trial.....

    by smart_money3000 Apr 7, 2016 10:04 PM jmyzal22 Apr 8, 2016 1:17 AM Flag

    In the last call they said money is not an issue for the phase 3. We'll get more clarity at the end of the month. There should be a dur-928 trial starting soon and data from the Nash single dose this quarter. It's for safety but if it show efficacy it's a home run one (not expecting it to be). Also the PDUFA for Remoxy will be announced this month according to pain.

  • Reply to

    Where PTIE goes DRRX is soon to follow

    by durectx Mar 31, 2016 1:14 PM jmyzal22 Mar 31, 2016 2:34 PM Flag

    I agree. Im excited to see the initial Nash data for dur-928 due 1 h 2016

  • Reply to


    by elite_pharm1 Mar 17, 2016 9:57 AM jmyzal22 Mar 28, 2016 9:29 PM Flag

    That's why you're posting on another board right?
    The they won't even put out revenue projections. The FDA let them waive the NDA fee of 2 million. If it was going to pass they would of charged them. Insider sold. Stocks down. Otc pump dump.

    Why are you posting about another company on this board?

  • Reply to

    Remoxy NDA, dur 928

    by jmyzal22 Mar 24, 2016 2:12 PM jmyzal22 Mar 25, 2016 3:42 PM Flag

    Thanks for your response and clarity.
    I agree that it will return to 2.50 to 3.50 and higher later in the year.

  • by jmyzal22 Mar 25, 2016 3:09 AM Flag

    What's up with douchebags touting their own stock on a different stock's board.
    Yeah I'm going drop my investment to get in yours off your pumping attempt.
    This board is for DRRX.

  • Reply to


    by elite_pharm1 Mar 17, 2016 9:57 AM jmyzal22 Mar 25, 2016 2:17 AM Flag

    I wonder why an insider sold 190k dollars worth after that news? Why not hold it after approval?

  • Reply to


    by elite_pharm1 Mar 17, 2016 9:57 AM jmyzal22 Mar 25, 2016 2:08 AM Flag

    That eltp drug is not going to get approved. They're a pump dump stock.
    on the pr for that the stock went up 4%. No ones confident in eltp

  • Reply to


    by elite_pharm1 Mar 17, 2016 9:57 AM jmyzal22 Mar 25, 2016 1:58 AM Flag

    That drug will not get approved

  • Reply to

    Remoxy NDA, dur 928

    by jmyzal22 Mar 24, 2016 2:12 PM jmyzal22 Mar 25, 2016 1:56 AM Flag

    Pfizer created their own abuse deterrent. The FDA gave them what they had to do, pain therapeutics confirmed with the FDA.

    As of July 23, Pain Therapeutics provided an update on REMOXY and I would like to repeat a few of the things that they said. First, they're focused on the NDA resubmission and have substantially completed the transition of REMOXY from their formal partner.
    Second, they've received - recently assessed the long-term stability of REMOXY and found that stability testing at 12 months was within the specifications. Third, they earlier had announced positive topline results from a human abuse potential study with REMOXY. This study demonstrated with statistical significance that both intact and chewed REMOXY "were less liked" that's in quotes, than immediate release oxycodone on the two primary endpoints and those endpoints were drug liking and drug high as determined by non-dependent recreational users.
    Fourth, Pain Therapeutics stated that their previous partner had reached a written agreement with the FDA on the specific content of an accessible NDA resubmission and that Pain Therapeutics had recently received written confirmation from the FDA that this key regulatory document remains valid and applies to their NDA resubmission.
    Lastly, they reiterated an expectation of resubmitting the NDA in the first quarter of 2016. After resubmission there will be a six month FDA review and as such we look forward to the potential approval of REMOXY in 2016.
    Although there are number of products and development, to-date no new control release abuse to turn oxycodone product has been approved, and the current estimate for resubmission would mean that REMOXY would be eligible for approval in the third quarter of 2016, so potentially a year from now we can have our first product on the market.

  • by jmyzal22 Mar 24, 2016 2:12 PM Flag

    Is anyone out there?
    The posts about stock picking websites are annoying.

    Remoxy NDA is due any day next week. I'm sure many investors have written it off but I still believe it will get across the goal line in 2016. I read the transcript from an earnings CC over the summer they said Pain has worked out all the issues with the drug.

    Does anyone know what's going on with Impax they've had the drug Eladur for 2 years now. Zogenix is waiting to partner relday.

    928 there will be data out on it next quarter, will this be data that starts to move us up?

    As for the share price. It's really cheap considering Remoxy could be on market next year. Posimir may partner anytime but they want the best deal because it's a better drug than what's out now.

    We should have more clarity on 928 in the next few months.

    Sentiment: Strong Buy